Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/30141
Başlık: Synthetically lethal BMN 673 (Talazoparib) loaded solid lipid nanoparticles for BRCA1 mutant triple negative breast cancer
Yazarlar: Eskiler, Gamze Güney
Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.
0000-0002-3820-424X
0000-0001-7904-883X
0000-0002-1619-6680
Çeçener, Gülşah
Egeli, Ünal
Tunca, Berrin
AAP-9988-2020
AAH-1420-2021
ABI-6078-2020
6508156530
55665145000
6602965754
Anahtar kelimeler: Chemistry
Pharmacology & pharmacy
BMN 673 (Talozoparib)
Poly ADP ribose polymerase (PARP) inhibitors
Solid lipid nanoparticles (SLNs)
Synthetic lethality
Triple negative breast cancer (TNBC)
Poly(ADP-ribose) polymerase-1/2 inhibitor
Parp inhibitor
DNA-repair
Vivo sensitivity
Highly polent
In-vitro
Resistance
Deficient
Mutations
Therapy
Yayın Tarihi: 15-Kas-2018
Yayıncı: Springer
Atıf: Eskiler, G. G. vd. (2018). ''Synthetically lethal BMN 673 (Talazoparib) loaded solid lipid nanoparticles for BRCA1 mutant triple negative breast cancer''. Pharmaceutical Research, 35(11).
Özet: Purpose The purpose of the study was to produce BMN 673 loaded solid lipid nanoparticles (SLNs) to improve its therapeutic index, to minimize toxicity and to overcome homologous recombination (HR)-mediated resistance.MethodsFirstly, BMN 673-SLNs were characterized using Nano Zeta Sizer. After treatment with different concentrations of BMN 673 and BMN 673-SLNs, cell viability of HCC1937((BRCA1-/-)), HCC1937-R (BMN 673-resistant) TNBC and MCF-10A normal human mammary breast epithelial cell line was analyzed by WST-1 assay. In an attempt to assess the therapeutic synthetic lethality efficacy of SLNs formulation, cell cycle arrest, DNA damage, mRNA expression levels of PARP1, H2AFX, RAD51 and BRCA1 gene were investigated. Then, PARP, ?H2AX, RAD51 and BRCA1 protein expression and nuclear localization were analyzed by western blot and immunofluorescence analysis.ResultsWhen compared with BMN 673, BMN 673-SLNs showed remarkably a decrease in HCC1937 and HCC1937-R cells with less damage to MCF-10A cells. BMN 673-SLNs significantly induced toxicity through double-stranded DNA breaks, G2/M cell cycle arrest and PARP cleavage in TNBC cells. Additionally, BMN 673-resistance was mediated by miR-107, miR-193b and miR-1255b targeting BRCA1 and RAD51 in HCC1937 and HCC1937-R cells. However, BMN 673-SLNs treatment could overcome HR-mediated resistance in TNBC cells.Conclusions As a result, our findings suggest that SLNs formulation strongly provides a synthetic lethal therapeutic potential in BRCA1 mutated sensitive and resistant TNBC cells.
URI: https://doi.org/10.1007/s11095-018-2502-6
link.springer.com/article/10.1007/s11095-018-2502-6
http://hdl.handle.net/11452/30141
ISSN: 0724-8741
1573-904X
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.